Related by context. Frequent words. (Click for all words.) 66 FDA Accepts 64 Announces Stockholder Approval 64 Completes Tender Offer 63 Extends Tender Offer 63 Presents Positive 62 Patient Enrollment 62 Stockholders Approve 61 Generic Version 61 Q2 Loss Narrows 61 Patent Infringement Lawsuit 61 Shareholder Letter 61 Receives Positive 60 Completes Enrollment 60 Inc Therapeutic Competitors 60 Patent Infringement Case 60 Regains Compliance With 60 Announces Share Repurchase 60 Regains Compliance 60 Adopts Shareholder Rights 60 Q2 Loss Widens 59 Inc. Nasdaq SEPR 59 Hold Fourth Quarter 59 Issues Guidance 59 Patent Lawsuit 59 Commence Trading 59 FDA Clears 58 Completes Private Placement 58 Stockholders Approve Merger 58 Announces Issuance 58 Positive Opinion 58 NASDAQ SHPGY 58 Provides Guidance 58 Announces Presentation 58 4Q Loss Widens 58 Company Nasdaq PRGO 58 BioDelivery Sciences 57 Webcast Annual Meeting 57 submitted Biologics License 57 Issues Statement Regarding 57 Announces Initiation 57 filed Solicitation Recommendation 57 Receives Regulatory 57 Pivotal Phase III 57 Updates Guidance 57 Cervical Cancer Vaccine 56 Option Grants 56 Report companiesandmarkets.com adds 56 Announces Definitive Agreement 56 Drug Candidate 56 Updates Status 56 Announces Intent 56 Inc. Nasdaq IMGN 56 Javelin Pharmaceuticals 56 Clinical Trial Results 56 Cholesterol Drug 56 Blood Thinner 56 Intent LoI 56 Director Shareholding 56 Receives Patent 56 FY# Guidance 56 Complete Response 56 Shareholder Vote 56 Complete Merger 56 Paragraph IV 56 Receives FDA Clearance 56 Anika Therapeutics 55 Receives Notice 55 Announces Shareholder Approval 55 Closes Financing 55 Continued Listing 55 Receives CE 55 Enters Into Letter 55 3rd Quarter Results 55 NYSE MYL 55 Commences Trading 55 Diet Pill 55 Acquires Exclusive 55 Initiates Phase 55 Vicuron Pharmaceuticals 55 Shareholder Approval 55 Drug Makers 55 Shareholder Update 55 Announces Termination 55 Offering Quick Facts 54 Exclusive License 54 Fibrocell Science Inc. 54 RNAi Therapeutics 54 Panel Rejects 54 Patent Covering 54 FDA Orphan Drug 54 Completes Merger 54 Initiate Phase 54 Exploit collaboration 54 Updates Shareholders 54 Waiting Period 54 Teva Pharma 54 Announces Signing 54 Patent Dispute 54 Commercialization Agreement 54 submitted Marketing Authorization 54 Protalix BioTherapeutics